Biotech Values

[DewDiligence]

CHMP approves GSK/THRX’s ICS/LABA combo for asthma and COPD:

http://finance.yahoo.com/news/relvar-tm-ellipta-tm-receives-173101087.html

In the EU, the brand name will be Relvar Ellipta (rather than Breo Ellipta in the US). Two fixed-dose combinations are available for asthma and one for COPD.

Revlar Ellipta should be not be confused with Anoro Ellipta, a LAMA/LABA combination using the same device that recently received an endorsement from an FDA advisory panel for COPD (#msg-91874192).